Search Results - "Eiermann, W"

Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial by Litton, J.K., Hurvitz, S.A., Mina, L.A., Rugo, H.S., Lee, K.-H., Gonçalves, A., Diab, S., Woodward, N., Goodwin, A., Yerushalmi, R., Roché, H., Im, Y.-H., Eiermann, W., Quek, R.G.W., Usari, T., Lanzalone, S., Czibere, A., Blum, J.L., Martin, M., Ettl, J.

“…In EMBRACA, talazoparib prolonged progression-free survival versus chemotherapy (hazard ratio [HR] 0.542 [95% confidence interval (CI) 0.413-0.711]; P <…”
Get full text

Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial by Denkert, C., Loibl, S., Müller, B.M., Eidtmann, H., Schmitt, W.D., Eiermann, W., Gerber, B., Tesch, H., Hilfrich, J., Huober, J., Fehm, T., Barinoff, J., Jackisch, C., Prinzler, J., Rüdiger, T., Erbstößer, E., Blohmer, J.U., Budczies, J., Mehta, K.M., von Minckwitz, G.

“…The proliferation marker Ki67 has been suggested as a promising cancer biomarker. As Ki67 needs an exact quantification, this marker is a prototype of a new…”
Get full text

Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12 by Gnant, M., Mlineritsch, B., Stoeger, H., Luschin-Ebengreuth, G., Knauer, M., Moik, M., Jakesz, R., Seifert, M., Taucher, S., Bjelic-Radisic, V., Balic, M., Eidtmann, H., Eiermann, W., Steger, G., Kwasny, W., Dubsky, P., Selim, U., Fitzal, F., Hochreiner, G., Wette, V., Sevelda, P., Ploner, F., Bartsch, R., Fesl, C., Greil, R.

“…These final results from ABCSG-12 confirm that twice-yearly ZOL safely enhances the efficacy of adjuvant endocrine therapy. Tamoxifen together with Goserelin…”
Get full text

Quality of life with talazoparib versus physician’s choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial by Ettl, J., Quek, R.G.W., Lee, K.-H., Rugo, H.S., Hurvitz, S., Gonçalves, A., Fehrenbacher, L., Yerushalmi, R., Mina, L.A., Martin, M., Roché, H., Im, Y.-H., Markova, D., Bhattacharyya, H., Hannah, A.L., Eiermann, W., Blum, J.L., Litton, J.K.

“…In the EMBRACA phase III trial, talazoparib (1mg daily, orally) demonstrated a statistically significant improvement in PFS versus physician’s choice of…”
Get full text

Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006 by Kaufmann, M., von Minckwitz, G., Bear, H.D., Buzdar, A., McGale, P., Bonnefoi, H., Colleoni, M., Denkert, C., Eiermann, W., Jackesz, R., Makris, A., Miller, W., Pierga, J.-Y., Semiglazov, V., Schneeweiss, A., Souchon, R., Stearns, V., Untch, M., Loibl, S.

“…Neoadjuvant (primary systemic) treatment has become a standard option for primary operable disease for patients who are candidates for adjuvant systemic…”
Get full text

Trastuzumab combined with chemotherapy for the treatment of HER2-positive metastatic breast cancer : Pivotal trial data by EIERMANN, W

“…A pivotal, randomized, multicenter, phase III trial was conducted to compare chemotherapy in combination with trastuzumab (Herceptin) vs. chemotherapy…”
Get full text

Outcome Prediction for Estrogen Receptor–Positive Breast Cancer Based on Postneoadjuvant Endocrine Therapy Tumor Characteristics by Ellis, Matthew J., Tao, Yu, Luo, Jingqin, A'Hern, Roger, Evans, Dean B., Bhatnagar, Ajay S., Chaudri Ross, Hilary A., von Kameke, Alexander, Miller, William R., Smith, Ian, Eiermann, Wolfgang, Dowsett, Mitch

“…Background Understanding how tumor response is related to relapse risk would help clinicians make decisions about additional treatment options for patients who…”
Get full text

The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use by Eiermann, W., Rezai, M., Kümmel, S., Kühn, T., Warm, M., Friedrichs, K., Schneeweiss, A., Markmann, S., Eggemann, H., Hilfrich, J., Jackisch, C., Witzel, I., Eidtmann, H., Bachinger, A., Hell, S., Blohmer, J.

“…We carried out a prospective clinical study to evaluate the impact of the Recurrence Score (RS) on treatment decisions in early breast cancer (EBC). A total of…”
Get full text

A pooled analysis of studies evaluating the impact of multi-gene assay testing on adjuvant treatment decisions for women with node-positive breast cancer by Braybrooke, J, Eiermann, W

Get full text

Locoregional treatments for triple-negative breast cancer by Eiermann, W, Vallis, K A

“…The absence of drug-targetable receptors in triple-negative breast cancer (TNBC) makes the use of targeted systemic therapy inappropriate for this breast…”
Get full text

Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial by Mackey, J.R., Pieńkowski, T., Crown, J., Sadeghi, S., Martin, M., Chan, A., Saleh, M., Sehdev, S., Provencher, L., Semiglazov, V., Press, M.F., Sauter, G., Lindsay, M., Houé, V., Buyse, M., Drevot, P., Hitier, S., Bensfia, S., Eiermann, W.

“…The optimal regimen for adjuvant breast cancer chemotherapy is undefined. We compared sequential to concurrent combination of doxorubicin and cyclophosphamide…”
Get full text

Results of Two Open-Label, Multicenter Phase II Studies of Docetaxel, Platinum Salts, and Trastuzumab in HER2-Positive Advanced Breast Cancer by Pegram, Mark D., Pienkowski, Tadeusz, Northfelt, Donald W., Eiermann, Wolfgang, Patel, Ravi, Fumoleau, Pierre, Quan, Eleonor, Crown, John, Toppmeyer, Deborah, Smylie, Michael, Riva, Alessandro, Blitz, Sandra, Press, Michael F., Reese, David, Lindsay, Mary-Ann, Slamon, Dennis J.

“…Background: Preclinical data indicate that docetaxel, platinum salts, and the combination of both drugs are highly synergistic with the anti-HER2 antibody…”
Get full text

Goserelin Versus Cyclophosphamide, Methotrexate, and Fluorouracil as Adjuvant Therapy in Premenopausal Patients With Node-Positive Breast Cancer: The Zoladex Early Breast Cancer Research Association Study by JONAT, W, KAUFMANN, M, EIERMANN, W, SZAKOLCZAI, I, PALMER, M, SCHUMACHER, M, GEBERTH, M, LISBOA, B, SAUERBREI, W, BLARNEY, R, CUZICK, J, NAMER, M, FOGELMAN, I, DE HAES, J. C, DE MATTEIS, A, STEWART, A

“…Current adjuvant therapies have improved survival for premenopausal patients with breast cancer but may have short-term toxic effects and long-term effects…”
Get full text

Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study by Eiermann, W., Paepke, S., Appfelstaedt, J., Llombart-Cussac, A., Eremin, J., Vinholes, J., Mauriac, L., Ellis, M., Lassus, M., Chaudri-Ross, H. A., Dugan, M., Borgs, M., Semiglazov, V.

“…Summary Background A randomized, double-blind, multicenter study was conducted to compare the anti-tumor activity of letrozole vs. tamoxifen in postmenopausal…”
Get full text

Pegfilgrastim ± ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study by von Minckwitz, G., Kümmel, S., du Bois, A., Eiermann, W., Eidtmann, H., Gerber, B., Hilfrich, J., Huober, J., Costa, S. D., Jackisch, C., Grasshoff, S.-T., Vescia, S., Skacel, T., Loibl, S., Mehta, K. M., Kaufmann, M.

“…Background: TAC (docetaxel/doxorubicin/cyclophosphamide) is associated with high incidences of grade 4 neutropenia and febrile neutropenia (FN). This analysis…”
Get full text

EMBRACA: Efficacy and safety in comparing talazoparib (TALA) with physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC) and a germline BRCA mutation (gBRCAm); BRCA1/BRCA2 subgroup analysis by Gonçalves, A., Eiermann, W., Rugo, H.S., Ettl, J., Hurvitz, S.A., Yerushalmi, R., Martín, M., Al-Adhami, M., Tudor, I.C., Blum, J.L., Hannah, A.L., Litton, J.K.

Get full text

EMBRACA: Comparison of efficacy and safety of talazoparib (TALA) and physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC), a germline BRCA1/2 mutation (gBRCAm), and prior platinum treatment by Martín, M., Eiermann, W., Rugo, H.S., Ettl, J., Hurvitz, S.A., Gonçalves, A., Yerushalmi, R., Markova, D., Tudor, I.C., Blum, J.L., Hannah, A.L., Litton, J.K.

Get full text

Statistical controversies in clinical research: statistical significance—too much of a good thing by Buyse, M., Hurvitz, S.A., Andre, F., Jiang, Z., Burris, H.A., Toi, M., Eiermann, W., Lindsay, M.-A., Slamon, D.

“…The use and interpretation of P values is a matter of debate in applied research. We argue that P values are useful as a pragmatic guide to interpret the…”
Get full text

Phase IB study of the EpCAM antibody adecatumumab combined with docetaxel in patients with EpCAM-positive relapsed or refractory advanced-stage breast cancer by Schmidt, M., Rüttinger, D., Sebastian, M., Hanusch, C.A., Marschner, N., Baeuerle, P.A., Wolf, A., Göppel, G., Oruzio, D., Schlimok, G., Steger, G.G., Wolf, C., Eiermann, W., Lang, A., Schuler, M.

“…Targeted therapy options in HER2-negative breast cancer are limited. This open-label, multicenter phase IB dose-escalation trial was conducted to determine…”
Get full text

Surgery following neoadjuvant therapy in patients with HER2-positive locally advanced or inflammatory breast cancer participating in the NeOAdjuvant Herceptin (NOAH) study by Semiglazov, V, Eiermann, W, Zambetti, M, Manikhas, A, Bozhok, A, Lluch, A, Tjulandin, S, Sabadell, M.D, Caballero, A, Valagussa, P, Baselga, J, Gianni, L

“…Abstract Aim To describe surgical outcomes in patients with HER2-positive locally advanced (LABC) or inflammatory breast cancer (IBC) participating in the…”
Get full text